● Recruiting

A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

Condition: Acute Ischemic Stroke · Sponsor: Lumosa Therapeutics Co., Ltd.

PhasePhase 2

Planned participants66

Who can joinAll sexes, 18 Years to 90 Years

Healthy volunteersNo

About this study

A phase IIb clinical study to evaluate the safety and efficacy of single or multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT).

This description comes directly from the study's public registry record.

Talk to the study team

Claire Sun · +886-2-26557918 · claire_sun@lumosa.com.tw

Always discuss trial participation with your own doctor first.

Locations (2)

CHI Memorial Hospital	Chattanooga, Tennessee, United States	Recruiting
Taichung Medical University	Taichung, Taiwan	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05198323